Citations for
1HAVCR2, IL10, IL27, NFIL3
An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction.
Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, Wang C, Tan DJ, Wu C, Rangachari M, Pertel T, Jin HT, Ahmed R, Anderson AC, Kuchroo VK.
Nat Commun 6:6072. doi: 10.1038/ncomms7072. Erratum in: Nat Commun. 2015;6:7657. 2015
2HAVCR2, IRF3, TLR4
Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages.
Jiang X, Yu J, Shi Q, Xiao Y, Wang W, Chen G, Zhao Z, Wang R, Xiao H, Hou C, Feng J, Ma Y, Shen B, Wang L, Li Y, Han G.
Clin Immunol 160(2):328-35. doi: 10.1016/j.clim.2015.07.008. Epub 2015 Jul 21. 2015
3HAVCR2
Tim-3 induces Th2-biased immunity and alternative macrophage activation during Schistosoma japonicum infection.
Hou N, Piao X, Liu S, Wu C, Chen Q.
Infect Immun 83(8):3074-82. doi: 10.1128/IAI.00517-15. Epub 2015 May 18. 2015
4HAVCR2
Microglia activity modulated by T cell Ig and mucin domain protein 3 (Tim-3).
Wang HW, Zhu XL, Qin LM, Qian HJ, Wang Y.
Cell Immunol 293(1):49-58. doi: 10.1016/j.cellimm.2014.12.005. Epub 2014 Dec 24. 2015
5HAVCR2
The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukaemia cells.
Prokhorov A, Gibbs BF, Bardelli M, Rüegg L, Fasler-Kan E, Varani L, Sumbayev VV.
Int J Biochem Cell Biol 59:11-20. doi: 10.1016/j.biocel.2014.11.017. Epub 2014 Dec 5. 2015
6CEACAM1, HAVCR2
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, Clayton KL, Raab M, Chen Q, Beauchemin N, Yazaki PJ, Pyzik M, Ostrowski MA, Glickman JN, Rudd CE, Ploegh HL, Franke A, Petsko GA, Kuchroo VK, Blumberg RS.
Nature 517(7534):386-90. doi: 10.1038/nature13848. Epub 2014 Oct 26. 2015
7HAVCR2, PDCD1
PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy.
Wang SC, Li YH, Piao HL, Hong XW, Zhang D, Xu YY, Tao Y, Wang Y, Yuan MM, Li DJ, Du MR.
Cell Death Dis 6:e1738. doi: 10.1038/cddis.2015.112. 2015
8HAVCR2
Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C, Chen X, Yu X, Zhu Y, Ma C, Xia R, Ma J, Gu C, Ye L, Wu D.
Int J Clin Exp Pathol 7(10):6880-8. eCollection 2014. 2014
9HAVCR2
Tim-3 negatively mediates natural killer cell function in LPS-induced endotoxic shock.
Hou H, Liu W, Wu S, Lu Y, Peng J, Zhu Y, Lu Y, Wang F, Sun Z.
PLoS One 9(10):e110585. doi: 10.1371/journal.pone.0110585. eCollection 2014. 2014
10HAVCR2
Tim-3 polymorphism downregulates gene expression and is involved in the susceptibility to ankylosing spondylitis.
Wang M, Ji B, Wang J, Cheng X, Zhou Q, Zhou J, Cao C, Guo Q.
DNA Cell Biol 33(10):723-8. doi: 10.1089/dna.2014.2456. Epub 2014 Jun 6. 2014
11HAVCR2
Regulation of T cell responses by the receptor molecule Tim-3.
Gorman JV, Colgan JD.
Immunol Res 59(1-3):56-65. doi: 10.1007/s12026-014-8524-1. Review. 2014
12HAVCR2
Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients.
Guo L, Yang X, Xia Q, Zhen J, Zhuang X, Peng T.
Clin Exp Med 14(4):383-8. doi: 10.1007/s10238-013-0264-3. Epub 2013 Nov 20. 2014
13HAVCR2, LGALS9
Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction.
Moriyama K, Kukita A, Li YJ, Uehara N, Zhang JQ, Takahashi I, Kukita T.
Lab Invest 94(11):1200-11. doi: 10.1038/labinvest.2014.107. Epub 2014 Sep 29. 2014
14HAVCR2, LGALS9
Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung.
Vega-Carrascal I, Bergin DA, McElvaney OJ, McCarthy C, Banville N, Pohl K, Hirashima M, Kuchroo VK, Reeves EP, McElvaney NG.
J Immunol 192(5):2418-31. doi: 10.4049/jimmunol.1300711. Epub 2014 Jan 29. 2014
15HAVCR2
A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3).
Möller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J.
J Biol Chem 288(48):34529-44. doi: 10.1074/jbc.M113.488478. Epub 2013 Oct 11. 2013
16HAVCR2
Dysregulated expression of T cell immunoglobulin and mucin domain 3 is associated with the disease severity and the outcome of patients with spontaneous intracerebral hemorrhage.
Liu X, You J, Zhao D, Guo M, Pan Y, Gao L, Liang X, Ma C.
Clin Biochem 46(15):1502-8. doi: 10.1016/j.clinbiochem.2013.04.030. Epub 2013 May 10. 2013
17BAG6, HAVCR2
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion.
Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, Angin M, Wakeham A, Greenfield EA, Sobel RA, Okada H, McKinnon PJ, Mak TW, Addo MM, Anderson AC, Kuchroo VK.
Nat Med 18(9):1394-400. 2012
18HAVCR2
T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer.
Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, Qi D.
Mol Biol Rep 39(11):9941-6. Epub 2012 Jun 26. 2012
19HAVCR2
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL.
Blood 119(16):3734-43. doi: 10.1182/blood-2011-11-392951. Epub 2012 Mar 1. 2012
20HAVCR2
Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes.
Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, Yao ZQ.
J Leukoc Biol 91(2):189-96. doi: 10.1189/jlb.1010591. Epub 2011 Aug 15. 2012
21HAVCR2, LGALS9
Galectin-9 regulates T helper cell function independently of Tim-3.
Su EW, Bi S, Kane LP.
Glycobiology 21(10):1258-65. doi: 10.1093/glycob/cwq214. Epub 2010 Dec 27. 2011
22HAVCR2, LGALS9
Tim3 binding to galectin-9 stimulates antimicrobial immunity.
Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK, Behar SM.
J Exp Med 207(11):2343-54. doi: 10.1084/jem.20100687. Epub 2010 Oct 11. 2010
23HAVCR2, TBX21
T-bet, a Th1 transcription factor regulates the expression of Tim-3.
Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos-Peyton CA, Glimcher LH, Kuchroo VK.
Eur J Immunol 40(3):859-66. doi: 10.1002/eji.200939842. 2010
24HAVCR2
TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.
Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK.
Eur J Immunol 39(9):2492-501. doi: 10.1002/eji.200939274. 2009
25HAVCR2
Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity.
Zhao J, Lei Z, Liu Y, Li B, Zhang L, Fang H, Song C, Wang X, Zhang GM, Feng ZH, Huang B.
J Immunol 182(10):6618-24. doi: 10.4049/jimmunol.0803876. 2009
26HAVCR2
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.
Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H, Okumura K.
Blood 113(16):3821-30. doi: 10.1182/blood-2008-10-185884. Epub 2009 Feb 17. 2009
27HAVCR2
TIM-3 as a therapeutic target in human inflammatory diseases.
Anderson DE.
Expert Opin Ther Targets 11(8):1005-9. Review. 2007
28HAVCR2
Dysregulated T cell expression of TIM3 in multiple sclerosis.
Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, Hafler DA.
J Exp Med 203(6):1413-8. Epub 2006 Jun 5. 2006
29HAVCR1, HAVCR2
T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.
Khademi M, IllŽs Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, Hafler DA, Kuchroo VK, Olsson T, Piehl F, Wallstršm E.
J Immunol 172(11):7169-76. 2004
30HAVCR2
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.
Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK.
Nature 415(6871):536-41. 2002